Press Releases

ProKidney to present at upcoming investor conferences

---

ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

---

ProKidney highlights key registrational program elements supporting advancement of REACT®

---

ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022 

---

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®

---

ProKidney Appoints Todd C. Girolamo as General Counsel

---

ProKidney to Present REACT® at 4th Annual CKD Summit

---

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease

---

ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III